Novavax: A Profile and a Comment. See Also: Why We Need More Firms to Develop Coronavirus Vaccines

Novavax Still Rallying After Grant
The Grant That Continues To Rally the Stock
Novavax (NVAX) stock continues its ascent following yesterday's announcement that the firm was granted up to $384 million by the coalition for Epidemic Preparedness innovation.

We remind that the grant is to help the advancement in the clinical development of the firm’s SARS-CoV-2 (

This content is for paid subscribers.
Please click here to subscribe or here to log in.